Streetbeat News

Products Services

IMMX

Immix Biopharma announced that an abstract on clinical data for its next-generation CAR-T therapy, NXC-201, targeting relapsed/refractory AL amyloidosis, has been accepted for oral presentation at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Baltimore, scheduled for May 7-11, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 1:38 pm

MA

Mastercard has entered into a strategic partnership with VoPay to enhance money movement for Canadians, simplifying both domestic and cross-border transactions for businesses and consumers.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 1:26 pm

RVSN

Rail Vision has signed a non-binding memorandum of understanding (MOU) with a leading railway technologies company for the distribution of its mainline and shunting yard products. This partnership aims to enhance Rail Vision's market presence and distribution capabilities.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 1:23 pm

GRRR

Gorilla Technology Group Inc. (NASDAQ:GRRR) introduced a new line of Security Convergence Devices, developed in collaboration with Lanner. These devices, featuring AI-based platform NetProbe, aim to redefine cybersecurity with advanced intrusion detection, DDoS protection, and real-time threat neutralization. Gorilla Technology targets a 2% market share in the rapidly growing Asia Pacific and MENA cybersecurity markets, projecting significant revenue growth and financial performance enhancement.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 1:18 pm

CRBU

Caribou Biosciences, Inc. (NASDAQ:CRBU), a leader in CRISPR genome-editing biopharmaceuticals, announced its presentation on Cas12a chRDNA genome-editing for hepatic gene disruption at ASGCT's 27th annual meeting in May 2024. The presentation will highlight the efficiency and functionality of Caribou's novel CRISPR platform, which offers more precise genome editing by using hybrid RNA-DNA guides (chRDNAs) to reduce off-target effects.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 1:15 pm

NVAX

Novavax Inc (NASDAQ:NVAX) shares rose after Shah Capital Management disclosed a 6.66% stake and nominated two directors for its board, criticizing the company's performance and suggesting strategic changes to improve business and share price.

Portfolio Pulse from Adam Eckert

April 15, 2024 | 1:14 pm

SATL

Satellogic Inc (NASDAQ:SATL) shares surged after announcing its subsidiary, Nettar Group, Inc., entered a note purchase agreement with Tether Investments Limited for $30 million in floating rate secured convertible promissory notes. The deal, which could expand to $50 million, aims to support Satellogic's mission to democratize geospatial data access. SATL shares rose 15.7% to $1.76 in premarket trading.

Portfolio Pulse from Shivani Kumaresan

April 15, 2024 | 1:05 pm

PBR

SLB

SLB has been awarded three completion contracts by Petrobras for the Buzios Field, aiming to support Petrobras' transition to an electrified production system. This move is expected to enhance completion reliability and boost production availability, although financial terms of the contracts were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 1:05 pm

MDB

MSFT

SNOW

Wedbush Securities analyst Daniel Ives predicts a significant increase in IT spending on AI technologies, estimating 8%-10% of IT budgets in 2024, up from less than 1% in 2023. This surge is expected to benefit major tech companies like Microsoft, Salesforce, Palantir, MongoDB, Oracle, Snowflake, and Elastic, with Microsoft and MongoDB receiving Outperform ratings and high price targets, while Snowflake has a Neutral rating.

Portfolio Pulse from Surbhi Jain

April 15, 2024 | 1:04 pm

RNAZ

TransCode Therapeutics has received FDA clearance to begin a Phase 1/2 clinical trial with TTX-MC138 for treating patients with advanced solid tumors. This marks a significant step forward in the company's development pipeline and could potentially impact its stock price positively in the short term as investors react to the news of the trial's approval.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 1:03 pm